LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease

Oncotarget

Volumn 6, Issue 39, 2015, Pages 41434-41452

  Ceccarelli, Sara ^a   Panera, Nadia ^a   Mina, Marco ^b   Gnani, Daniela ^a   De Stefanis, Cristiano ^a   Crudele, Annalisa ^a   Rychlicki, Chiara ^c   Petrini, Stefania ^a   Bruscalupi, Giovannella ^d   Agostinelli, Laura ^c   Stronati, Laura ^e   Cucchiara, Salvatore ^d   Musso, Giovanni ^f   Furlanello, Cesare ^b   Svegliati Baroni, Gianluca ^c   Nobili, Valerio ^a   Alisi, Anna ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b FONDAZIONE BRUNO KESSLER   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ENEA   (Italy)

^f GRADENIGO HOSPITAL   (Italy)

Author keywords

Fibrosis; Inflammation; LITAF; LPS; NAFLD; Pathology section

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; IL1B PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; LITAF PROTEIN, HUMAN; LITAF PROTEIN, MOUSE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEPATITIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; STELLATE CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BINDING SITE; CELL LINE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEPATIC STELLATE CELL; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; BINDING SITES; CELL LINE; CYTOKINES; FEMALE; HEPATIC STELLATE CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 84951756632     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5163     Document Type: Article

References (63)

1. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signalling in chronic liver diseases. Hepatol Int. 2010; 4:659-672.
2. Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2010; 2010:362847.
3. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo K. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995; 22:165-172.
4. Chan CC, Hwang SJ, Lee FY, Wang SS, Chang FY, Li CP, Chu CJ, Lu RH, Lee SD. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol. 1997; 32:942-946.
5. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010; 50:645-649.
6. Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C, Obermeier F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011; 55:1391-1399.
7. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007; 13:1324-1332.
8. Spruss A, Kanuri G, Wagnerberger S, Haub S, BischoffSC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009; 50:1094-1104.
9. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis. J Hepatol. 2007; 47:571-579.
10. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011; 56:1524-1534.
11. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482:179-185.
12. Duseja A, Chawla YK. Obesity and NAFLD: The role of bacteria and microbiota. Clin Liver Dis. 2014; 18:59-71.
13. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997; 389:300-305.
14. Myokai F, Takashiba S, Lebo R, Amar S. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci U S A. 1999; 96:4518-4523.
15. Merrill JC, You J, Constable C, Leeman SE, Amar S. Whole-body deletion of LPS-induced TNF-a factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis. Proc Natl Acad Sci U S A. 2011; 108:21247-21252.
16. Tang X, Fenton MJ, Amar S. Identification and functional characterization of a novel binding site on TNF-alpha promoter. Proc Natl Acad Sci U S A. 2003; 100:4096-4101.
17. Tang X, Metzger D, Leeman S, Amar S. LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: Evidence for LITAF-dependent LPS signaling pathways. Proc Natl Acad Sci U S A. 2006; 103:13777-13782.
18. Ji ZZ, Dai Z, Xu YC. A new tumor necrosis factor (TNF)-a regulator, lipopolysaccharides-induced TNF-a factor, is associated with obesity and insulin resistance. Chin Med J (Engl). 2011; 124:177-182.
19. Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011; 91:283-293.
20. Alisi A, Nobili V, Ceccarelli S, Panera N, De Stefanis C, De Vito R, Vitali R, Bedogni G, Balsano C, Cucchiara S, Stronati L. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert Rev Mol Diagn. 2014; 14:763-771.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313-1321.
22. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 1996; 23:1189-1199.
23. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis. 2007; 27:413-426.
24. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001; 21:397-416.
25. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134:1655-1669.
26. Benedetti A, Di Sario A, Casini A, RidolfiF, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G. Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology. 2001; 120:545-556.
27. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int. 2008; 28:1052-1064.
28. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007; 56:284-292.
29. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012; 590:447-458.
30. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014; 59:1738-1749.
31. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005; 54:142-151.
32. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998; 101:1163-1174.
33. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59:583-594.
34. Alisi A, Carpino G, Nobili V. Paediatric nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2013; 29:279-284.
35. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014; 147:754-764.
36. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010; 7:195-203.
37. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010; 42:320-330.
38. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014; 15:8591-8638.
39. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008; 14:72-81.
40. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013; 58:1218-1229.
41. De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des. 2013; 19:5239-5249.
42. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21:27-41.
43. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010; 7:15.
44. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alphainduced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol. 2009; 51:168-175.
45. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49:1877-1887.
46. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010; 7:691-701.
47. Rombouts K, Marra F. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Dig Dis. 2010; 28:229-235.
48. Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012; 47:215-225.
49. Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and arcinogenesis. J Gastroenterol Hepatol. 2013; 1:38-42.
50. Ceccarelli S, Nobili V, Alisi A. Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World J Gastroenterol. 2014; 20:16443-16451.
51. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003; 37:1043-1055.
52. Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2005; 289:G571-578.
53. Eaton HE, Desrochers G, Drory SB, Metcalf J, Angers A, Brunetti CR. SIMPLE/LITAF expression induces the translocation of the ubiquitin ligase itch towards the lysosomal compartments. PLoS One. 2011; 6:e16873.
54. Thirunavukkarasu C, Watkins SC, Gandhi CR. Mechanisms of endotoxin-induced nitric oxide, interleukin-6 and tumor necrosis factor-a production in activated rat hepatic stellate cells: role of p38MAPK. Hepatology. 2006; 44:389-398.
55. Könner AC, Brüning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab. 2011; 22:16-23.
56. Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Olteanu S, Barshack I, Dotan S, Voronov E, Dinarello CA, Apte RN, Harats D. Lack of interleukin-1a or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol. 2011; 5:1086-1094.
57. Martinon F, Burns K, Tschopp J. The inflammasome: a molecularplatform triggering activation of inflammatory caspases andprocessing of proIL-beta. Mol Cell. 2002; 10:417-426.
58. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012; 57:642-654.
59. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013; 13:679-692.
60. Otsu N. A threshold selection method from gray-level histograms. Automatica. 1875; 11:23-27.
61. Beucher S, Lantuéjoul C. Use of watersheds in contour detection. International workshop on image processing. 1979; Vol 17:2.1-2.12.
62. Coelho LP. Mahotas: Open source software for scriptable computer vision. J Open Res Softw. 2013; 1: e3.
63. Alisi A, Piemonte F, Pastore A, Panera N, Passarelli C, Tozzi G, Petrini S, Pietrobattista A, Bottazzo GF, Nobili V. Glutathionylation of p65NF-kappaB correlates with proliferating/apoptotic hepatoma cells exposed to pro-and anti-oxidants. Int J Mol Med. 2009; 24:319-326.